TIG3 Antibody (LW-M10): sc-135579
- TIG3 Antibody (LW-M10) is a mouse monoclonal IgG2a κ TIG3 antibody provided at 100 µg/ml
- raised against recombinant TIG3 protein of human origin
- recommended for detection of TIG3 of human origin by WB, IP and ELISA
- At present, we have not yet completed the identification of the preferred secondary detection reagent(s) for TIG3 Antibody (LW-M10). This work is in progress.
QUICK LINKS
TIG3 Antibody (LW-M10) is a mouse monoclonal IgG2a kappa light chain antibody that detects TIG3 protein of human origin by western blotting (WB), immunoprecipitation (IP), and enzyme-linked immunosorbent assay (ELISA). Anti-TIG3 antibody (LW-M10) is available as a non-conjugated monoclonal isotype antibody. TIG3, a member of the H-rev107 family, plays a crucial role as a growth regulator and is essential for mediating the growth-suppressive effects of retinoids, which are vital in cancer therapy and skin health. TIG3 is widely expressed across various tissues, although absent in heart, testis, and brain, highlighting specific functional roles in other organs. TIG3 expression is particularly significant in skin, hair follicles, and endothelial cells, where TIG3 contributes to the regulation of cellular growth and differentiation. TIG3 is activated by tazarotene, a synthetic retinoid, which underscores TIG3′s importance in therapeutic contexts, especially in the treatment of skin disorders and certain cancers. Using TIG3 monoclonal antibody (LW-M10) in research can provide valuable insights into the mechanisms of retinoid action and tumor-suppressive properties of TIG proteins.
Alexa Fluor® is a trademark of Molecular Probes Inc., OR., USA
LI-COR® and Odyssey® are registered trademarks of LI-COR Biosciences
TIG3 Antibody (LW-M10) References:
- Hypermethylation and silencing of the putative tumor suppressor Tazarotene-induced gene 1 in human cancers. | Youssef, EM., et al. 2004. Cancer Res. 64: 2411-7. PMID: 15059893
- Optimal use of a panel of methylation markers with GSTP1 hypermethylation in the diagnosis of prostate adenocarcinoma. | Tokumaru, Y., et al. 2004. Clin Cancer Res. 10: 5518-22. PMID: 15328191
- Silencing of the retinoid response gene TIG1 by promoter hypermethylation in nasopharyngeal carcinoma. | Kwong, J., et al. 2005. Int J Cancer. 113: 386-92. PMID: 15455391
- An inflammatory role for the mammalian carboxypeptidase inhibitor latexin: relationship to cystatins and the tumor suppressor TIG1. | Aagaard, A., et al. 2005. Structure. 13: 309-17. PMID: 15698574
- Discovery of epigenetically masked tumor suppressor genes in endometrial cancer. | Takai, N., et al. 2005. Mol Cancer Res. 3: 261-9. PMID: 15886297
- TIG3: a regulator of type I transglutaminase activity in epidermis. | Eckert, RL., et al. 2009. Amino Acids. 36: 739-46. PMID: 18612777
- TIG3 tumor suppressor-dependent organelle redistribution and apoptosis in skin cancer cells. | Scharadin, TM., et al. 2011. PLoS One. 6: e23230. PMID: 21858038
- TIG3 interaction at the centrosome alters microtubule distribution and centrosome function. | Scharadin, TM., et al. 2012. J Cell Sci. 125: 2604-14. PMID: 22427689
- TIG3: an important regulator of keratinocyte proliferation and survival. | Scharadin, TM. and Eckert, RL. 2014. J Invest Dermatol. 134: 1811-1816. PMID: 24599174
- Structural and functional characterization of tumor suppressors TIG3 and H-REV107. | Wei, H., et al. 2015. FEBS Lett. 589: 1179-86. PMID: 25871522
- High expression of TIG3 predicts poor survival in patients with primary glioblastoma. | Wang, H., et al. 2017. Tumour Biol. 39: 1010428317712135. PMID: 28639915
- Identification and characterization of a retinoid-induced class II tumor suppressor/growth regulatory gene. | DiSepio, D., et al. 1998. Proc Natl Acad Sci U S A. 95: 14811-5. PMID: 9843971
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
TIG3 Antibody (LW-M10) | sc-135579 | 100 µg/ml | $339.00 |